---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000078"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T21:35:38.945181+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth

## Summary
- Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).
- GAAP diluted EPS $0.25; non-GAAP diluted EPS $0.31, vs $0.22 and $0.28 last year.
- CABOMETYX remains top TKI in RCC; growth driven by first-line combo with nivolumab.
- Pipeline advances: zanzalintinib STELLAR-001 enrollment complete; XB002 dose selected.
- Upcoming catalysts: CONTACT-02 readout, COSMIC-313 OS analysis, R&D Day Dec 12.

## SEC filing metadata
- accession: 0000939767-23-000078
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/0000939767-23-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/exel-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000078
- JSON: https://secwatch.observer/filing/0000939767-23-000078.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000078.txt

## Key facts
- Earnings Releases
  EXELIXIS, INC. reported the quarter ended June 30, 2023 results: revenue Total revenues of $469.8 million, net income GAAP net income of $81.2 million, or $0.25 per share, EPS $0.25 per share.
  - Period: the quarter ended June 30, 2023
  - Revenue: Total revenues of $469.8 million
  - Net income: GAAP net income of $81.2 million, or $0.25 per share
  - EPS: $0.25 per share
  - Result: reported results
  source text: Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/0000939767-23-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.